PD-L1 detection using (89)Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response

BACKGROUND: Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. Most studies of PD-L1 are limited by evaluation in primary rather than metastat...

Descripción completa

Detalles Bibliográficos
Autores principales: Vento, Joseph, Mulgaonkar, Aditi, Woolford, Layton, Nham, Kien, Christie, Alana, Bagrodia, Aditya, de Leon, Alberto Diaz, Hannan, Raquibul, Bowman, Isaac, McKay, Renee M., Kapur, Payal, Hao, Guiyang, Sun, Xiankai, Brugarolas, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545669/
https://www.ncbi.nlm.nih.gov/pubmed/31155004
http://dx.doi.org/10.1186/s40425-019-0607-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545669/
https://www.ncbi.nlm.nih.gov/pubmed/31155004
http://dx.doi.org/10.1186/s40425-019-0607-z

Ejemplares similares